Jonathan Allan - Mar 15, 2024 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
GENERAL COUNSEL & CORP SEC
Signature
/s/ Stephen Tulipano, Attorney-in-Fact
Stock symbol
STOK
Transactions as of
Mar 15, 2024
Transactions value $
-$14,326
Form type
4
Date filed
3/19/2024, 08:29 PM
Previous filing
Dec 5, 2023
Next filing
Jun 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $0 +7.48K +287.72% $0.00 10.1K Mar 15, 2024 Direct F1
transaction STOK Common Stock Sale -$14.3K -2.35K -23.32% $6.10 7.72K Mar 19, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Restricted Stock Units Options Exercise $0 -7.48K -25% $0.00 22.4K Mar 15, 2024 Common Stock 7.48K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported total includes an aggregate 2,598 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
F2 The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.94 to $6.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F5 The award vested or vests as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.